Cortex Pharmaceuticals, Inc.

Irvine, CA 92618

SBIR Award Summary

Total Number of Awards 9
Total Value of Awards $1.84MM
First Award Date 05/15/90
Most Recent Award Date 09/01/02

Key Personnel

Last Name Name Awards Contact
Cavanaugh Kathleen P Cavanaugh 1
Eveleth David D Eveleth 1
Johnson Steven A Johnson 3
Rogers Gary A Rogers 4

9 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/02 - 08/31/05

DESCRIPTION (adapted from applicant's abstract): Despite recent clinical efforts, there is currently no effective treatment for brain damage due to stroke. As a new pharmacological approach, we propose to test the potential of Ampakines, which are novel allosteric positive modulators of AMPA receptors, as possibl...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/02 - 08/31/05

DESCRIPTION: (Adapted From the Applicant's Abstract) Currently available antipsychotics effectively control positive symptoms (hallucinations, delusions), but persistent negative symptoms (withdrawal, apathy) and cognitive deficits are little affected and can be quite disabling in most patients with schizop...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/25/01 - 08/31/02

DESCRIPTION: (Adapted From the Applicant's Abstract) Currently available antipsychotics effectively control positive symptoms (hallucinations, delusions), but persistent negative symptoms (withdrawal, apathy) and cognitive deficits are little affected and can be quite disabling in most patients with schizop...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/01 - 08/31/02

DESCRIPTION (adapted from applicant's abstract): Despite recent clinical efforts, there is currently no effective treatment for brain damage due to stroke. As a new pharmacological approach, we propose to test the potential of Ampakines, which are novel allosteric positive modulators of AMPA receptors, as possibl...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/00 - 08/31/01

DESCRIPTION (adapted from applicant's abstract): Despite recent clinical efforts, there is currently no effective treatment for brain damage due to stroke. As a new pharmacological approach, we propose to test the potential of Ampakines, which are novel allosteric positive modulators of AMPA receptors, as possibl...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/21/99 - 03/31/00

DESCRIPTION: (Applicant's abstract) There is a great need for a safe drug therapy for stroke that does not involve transmitter receptor blockade or haemorrhagic risk. Ampakines are a novel group of allosteric positive modulators that target AMPA-type glutamate receptors. Ampakines improve learnin...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/01/99 - 07/31/99

DESCRIPTION: (Applicant's abstract) Current antipsychotic drugs produce many side effects, but treat only some of the symptoms. Modern theories of schizophrenia are expanding from the traditional dopamine hypothesis to include the concept of reduced glutamatergic function. A new pharmacology that increas...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/93 - 10/31/93

Peripheral neuropathy is a common and clinically significant complication of cancer chemotherapy. Importantly, this neuropathy is a dose-limiting effect of many chemotherapeutic agents. Since the clinical outcome is often related to the tolerated dose, a drug which reduces the neuropathy would increase the tolerated dose and thus increase surv...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/15/90 - 01/31/91